In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …

Introduction Treatment of acute myeloid leukemia (AML) has changed dramatically in the
past ten years with the approval of targeted agents, the first of which was the anti-CD33 …

After being in the therapeutic wilderness for several decades, acute myeloid leukemia has
been recently thrust into the limelight with a series of drug approvals. Technical refinements …

Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …

Through the years gemtuzumab ozogamicin (GO) has moved from a panacea in the
treatment of acute myeloid leukemia (AML) to a pariah and back again. Early promise of …

Abstract On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin
(Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a …

Abstract On 1 September 2017, the US Food and Drug Administration (FDA) approved
gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33+ …

Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …

Abstract On September 2, 2017, the US Food and Drug Administration approved
gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed …

Simple Summary Gemtuzumab Ozogamicin (GO) is a drug approved for the treatment of
acute myeloid leukemia (AML). It targets leukemic cells that express the CD33 molecule on …